Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Verona – page 4

434 clinical trials in Verona, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Verona at a glance
434
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

434 trials in Verona

Open in trial search

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer

Recruiting

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acute promyelocytic leukaemia

Recruiting

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to assess the safety of anumigilimab in adults with sickle cell disease

Recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anumigilimab
  • Sponsor:CSL Behring LLC

Type 2 diabetes mellitus+1

Recruiting

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Ductal adenocarcinoma of pancreas

Recruiting

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
  • Sponsor:Revolution Medicines Inc.

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Mantle cell lymphoma

Recruiting

Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Fondazione Italiana Linfomi Ets

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Verona

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on acute ischemic stroke treatment and neurological conditions including narcolepsy and Dravet Syndrome. Studies evaluate new therapeutic approaches for improving patient outcomes and managing symptoms.

  • Stroke Treatment Optimization
  • Sleep Disorders Management
  • Seizure Control

Multiple trials exploring novel medications and treatment combinations for better patient care.

02 Oncology Research

Comprehensive studies targeting various cancers including gastric cancer, Merkel cell carcinoma, and metastatic colorectal cancer. Research focuses on innovative treatment combinations and targeted therapies.

  • Advanced Solid Tumors
  • Hematological Malignancies
  • Immunotherapy Approaches

Trials investigating novel drug combinations and personalized treatment strategies.

03 Autoimmune Conditions

Clinical investigations into Sjögren's Syndrome, systemic sclerosis, and other autoimmune disorders. Studies evaluate new biological treatments and their long-term effectiveness.

  • Connective Tissue Disorders
  • Chronic Inflammatory Conditions
  • Novel Therapeutic Approaches

Research focusing on improving quality of life and disease management for patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.